1. Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real‐life cohort. Issue 4 (9th December 2016) Authors: Alonso, S.; Riveiro‐Barciela, M.; Fernandez, I.; Rincón, D.; Real, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernandez‐Carrillo, C.; Polo, B.; Carrión, J. A.; Gómez, A.; Devesa, M. J.; Baliellas, C.; Castro, Á.; Ampuero, J.; Granados, R.; Pascasio, J. M.; Rubín, A.; Salmeron, J. Journal: Journal of viral hepatitis Issue: Volume 24:Issue 4(2017) Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Undetectable HCV‐RNA at treatment‐week 8 results in high‐sustained virological response in HCV G1 treatment‐experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Issue 5 (14th October 2014) Authors: Bruno, S.; Bollani, S.; Zignego, A. L.; Pascasio, J. M.; Magni, C.; Ciancio, A.; Caremani, M.; Mangia, A.; Marenco, S.; Piovesan, S.; Chemello, L.; Babudieri, S.; Moretti, A.; Gea, F.; Colletta, C.; Perez‐Alvarez, R.; Forns, X.; Larrubia, J. R.; Arenas, J.; Crespo, J. Journal: Journal of viral hepatitis Issue: Volume 22:Issue 5(2015) Page Start: 469 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗